lefamulin (Xenleta) Report issue

Small molecule Approved FDA Fast Track FDA Priority Review FDA
AACT ChEMBL DrugBank PubChem

Active Ingredient History

NOW
  • Now
LEFAMULIN is a pleuromutilin antibiotic under development for the treatment of community-acquired bacterial pneumonia, as well as acute bacterial skin and skin structure infections. It inhibits bacterial protein synthesis by binding to the peptidyl transferase center of the 50S ribosome, resulting in the cessation of bacterial growth.   NCATS

Chemistry

  • SMILES: C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CS[C@@H]4CC[C@@H](N)C[C@H]4O
  • InChIKey: KPVIXBKIJXZQJX-CSOZIWFHSA-N
  • Mol. Mass: 507.726
  • ALogP: 3.87
  • ChEMBL Molecule:
    lefamulin  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$77.8983 - $127.1357
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

bc-3781 | lefamulin

Organizations (3)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (1)


 

Pneumonia, Bacterial (approved 2019)

Experimental Indications - Clinical Trial Phases 1-4 (5)


 

Bacterial Infections (Phase 2)

Community-Acquired Infections (Phase 3)

Healthy Volunteers (Phase 1)

Infections (Phase 2)

Mycoplasma (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue